Introduction: Prior randomized controlled trials comparing bladder preservation to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) closed due to lack of accrual.Given that none are foreseen, we used propensity scores to compare trimodality therapy (TMT, maximal transurethral resection of bladder tumor followed by concurrent chemoradiation) to RC. Methods: This retrospective analysis included 722 patients with clinical stage T2-T4N0M0 MIBC urothelial carcinoma of the bladder (440RC/282TMT) who would have been eligible for both approaches, treated at three university centers from 2005-2017.All patients had solitary tumors <7 cm, no or unilateral hydronephrosis, and no extensive/multifocal carcinoma in situ.Differences in survival outcomes by treatment were evaluated using propensity scores incorporated in: 1) propensity score-matching (PSM) using logistic regression and 3:1 matching with replacement; and 2) inverse probability treatment weighting (IPTW).Results: A total of 440/1492 (29.5%) of all MIBC surgical candidates were also candidates for TMT.The matched cohort comprised of 1119 patients (837 RC vs. 282 TMT).After matching, age (71.4 vs. 71.6),cT2 stage (90.2 vs. 90.4%),hydronephrosis (11.6 vs. 9.6%), and (neo)-adjuvant chemotherapy (60.4 vs. 56.4%)were similar between groups.Salvage cystectomy was performed in 38 (13%) TMT patients.There was no difference in five-year metastatic-free survival probabilities for RC and TMT either with IPTW (74% vs. 75%,p=0.40)or PSM (78%vs.76%, p=0.62), respectively.The five-year cancer-specific survival probabilities for RC and TMT using IPTW and PSM were 81% vs. 84%, (p=0.07) and 83% vs. 85% (p=0.06),respectively.Overall survival favored TMT (IPTW 66% vs. 73%, p=0.007;PSM 72% vs. 77%, p=0.005).Outcomes for RC and TMT were not statistically different among centers for CSS and MFS (p=0.22-0.90).Conclusions: This multi-institutional study provides the best evidence to date demonstrating similar oncological outcomes between RC and TMT for select MIBC patients.